|
|
|
|
|
|
|
|
|
11.11.25 - 23:12
|
Alcon Inc. Q3 Profit Decreases, Misses Estimates (AFX)
|
|
|
BRUSSELS (dpa-AFX) - Alcon Inc. (ALC) reported earnings for third quarter that Decreased from the same period last year and missed the Street estimates.The company's earnings totaled $237 million,......
|
|
|
|
|
11.11.25 - 22:39
|
Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds (Business Wire)
|
|
|
Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024
Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79
Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders
Full-year 2025 guidance maintained
Ad Hoc Announcement Pursuant to Art. 53 LRGENEVA--(BUSINESS WIRE)--Regulatory News:
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.48 and core diluted earnings per share2 of $0.79 in the third quarter of 2025.
"As expected, we saw encouraging topline growth in the third quarter, driven by strong accele...
|
|
|
|
|
10.11.25 - 14:06
|
Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process (Business Wire)
|
|
|
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process
Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right TimeNEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) to Alcon Inc. (“Alcon”) (NYSE: ALC).
Neal C. Bradsher, Founder and President of Broadwood, said:
“For more than three months, we have been telling the Board of Directors that its decision to sell STAAR to Alcon came at the wrong time, resulted from the wrong process, and was at the wrong price. The vast majority of shareholders and all three major proxy advisory firms shared our perspective and overwhelmingly opposed this misbegotten transaction.
We ar...
|
|
|
|
|
|
|
07.11.25 - 16:15
|
STAAR Surgical Announces Amendments to Alcon Merger Agreement (Business Wire)
|
|
|
30-Day Go-Shop Period to Actively Solicit Other Third-Party Proposals
No Termination Fee Payable to Alcon if STAAR Terminates Merger Agreement to Accept a Superior Proposal from a Qualified Bidder
Alcon Waives All Matching Rights for Third-Party Proposals
Alcon Waives Information Rights During the Go Shop Period
Alcon to Engage with STAAR Stockholders to Solicit Support in Favor of the Merger Proposal
STAAR Special Meeting of Stockholders Postponed to December 19, 2025 to Provide Time for Third-Party Proposals
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the Company has agreed with Alcon Inc. (SIX/NYSE: ALC) to amend their merger agreement to allow proactive solicitation by STAAR of third-party proposals to maximize value for all STAAR stockholders.
The amended agreement includes:
A new 30-day go-shop period: The new go-shop period e...
|
|
|
|
|
04.11.25 - 07:06
|
Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders (Business Wire)
|
|
|
GENEVA--(BUSINESS WIRE)--Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care, today announced that it has filed an investor presentation in support of the proposed acquisition of STAAR Surgical Company (NASDAQ: STAA) with the U.S. Securities and Exchange Commission (SEC). Alcon plans to initiate outreach to STAAR stockholders and the presentation highlights key considerations for these discussions, including:
The proposed merger represents a premium that significantly exceeds the median premium of comparable MedTech transactions and offers certain value to STAAR stockholders.1
The Broadwood Partners-led opposition campaign is an attempt at a “silent takeover” of STAAR Surgical. Broadwood has proposed removing STAAR board members and installing its own slate of directors, all without offering any premium or alternative transaction to stockholders. This effort, in Alcon's view, risks disenfranchising the broader stockholder base and undermining the value-maximizing opportunity current...
|
|
|
|
|
27.10.25 - 13:03
|
STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon (Business Wire)
|
|
|
STAAR Special Meeting of Stockholders Postponed to December 3, 2025LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) announced that, in light of ongoing discussions with Alcon (SIX/NYSE: ALC), STAAR's Special Meeting of Stockholders in connection with STAAR's merger agreement with Alcon (the “Special Meeting”), which was previously adjourned until November 6, 2025 at 8:30 a.m. Pacific Time, has been postponed until December 3, 2025 at 8:30 a.m. Pacific Time. The new record date for the Special Meeting is the close of business on October 24, 2025. Stockholders who hold shares as of the record date will be eligible to vote at the postponed Special Meeting on December 3, 2025, and STAAR will be providing a notice of the meeting and other materials to such stockholders in advance of the meeting date.
Stockholders with questions about voting their shares should contact STAAR's proxy solicitor, Innisfree M&A Incorporated...
|
|
|
|
|
|
|
23.10.25 - 18:15
|
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders (Business Wire)
|
|
|
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that STAAR and Alcon have agreed to adjourn STAAR's Special Meeting of Stockholders (the “Special Meeting”) scheduled for October 23, 2025, in connection with STAAR's merger agreement with Alcon. No other business will be conducted at the Special Meeting.
STAAR is adjourning the Special Meeting until 8:30 a.m. Pacific Time on November 6, 2025. The record date for STAAR stockholders eligible to vote at the Special Meeting remains the close of business on September 12, 2025.
Stockholders with questions about voting their shares should contact STAAR's proxy solicitor, Innisfree M&A Incorporated, toll-free at +1 877-750-8233. Banks and brokerage firms, please call +1 212-750-5833.
About Alcon
Alcon helps people see brilliantly. As the global le...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
